EXCLUSIVE BREAKING NEWS
The clearance marks the introduction of the calcium-acrylic modified polymer (CAMP) composite, representing a significant advancement in structural orthopedic implants.
DAYTON, OH – Orthomod LLC, a medical device company driving material innovations for orthopedics and spine surgery, announces FDA clearance of its new MOD-C™ cervical intervertebral implant family for the treatment of degenerative disc disease of the cervical spine from C2-T1. This milestone represents the clearance of a novel, permanent biomaterial composite for use in orthopedic and spine surgery.
CAMP (calcium-acrylic modified polymer) is a unique composite of an acrylic polymer and synthetic beta-tricalcium phosphate/hydroxyapatite (B-TCP/HA). The product of extensive development efforts by biomaterials experts, the CAMP platform introduces an important new material option for structural orthopedic implants. Designed with a broad range of potential applications in spine, reconstructive orthopedics, dentistry, sports medicine, and oncology, the CAMP platform promises to address a significant share of the $60 billion orthopedic implant market.
“This clearance marks an important milestone not only for Orthomod, but for the broader field of orthopedic biomaterials,” states David Kirschman, M.D., CEO of Orthomod. “For decades, spine surgeons have faced a duopoly in choices for a structural interbody implant: titanium or PEEK. CAMP is a third-generation material, engineered to provide a more bone-like alternative to legacy implant materials. Like bone, CAMP is microporous and hydrophilic, allowing ionic transfer between its mineral components at the implant interface. The CAMP platform offers practically infinite possibilities for matching the implant to clinical needs.”
The MOD-C implant family, planned for clinical launch in the second half of 2026, was developed to address the longstanding need for a cervical interbody device that provides immediate structural support while utilizing biphasic calcium phosphate incorporated into a microporous polymer matrix. To evaluate the biological response, Orthomod assessed the MOD-C material in pre-clinical studies using an osseointegration model in both cortical and cancellous sites over a 26-week integration period. By combining structural integrity, radiographic visibility, and a B-TCP/HA composite interface, MOD-C offers surgeons a compelling new option. The device enters the growing $3 billion cervical fusion market, with 200,000 implants placed in the US annually.
The FDA clearance of MOD-C (K242303) represents the first step in Orthomod’s broader platform strategy. The company is advancing additional products based on CAMP across multiple orthopedic, spine, and dental applications, aiming to establish a new class of implants that combine advanced biomaterial science with high structural integrity.
About Orthomod LLC Orthomod LLC is headquartered in Dayton, Ohio, and is focused on the development of advanced biomaterials and implant technologies for musculoskeletal applications. Its CAMP platform is designed to enable a new generation of implants that support and protect the skeletal system using advanced composite structures.
Contact: Matt Otten Orthomod, LLC 350 Fame Road Dayton, OH 45449 matto@orthomod.com
